Stock DNA
Pharmaceuticals & Biotechnology
GBP 58 Million (Micro Cap)
19.00
NA
0.00%
-1.42
86.80%
15.27
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2011)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.62%
0%
7.62%
6 Months
45.81%
0%
45.81%
1 Year
55.86%
0%
55.86%
2 Years
-27.1%
0%
-27.1%
3 Years
-74.61%
0%
-74.61%
4 Years
-99.41%
0%
-99.41%
5 Years
-99.41%
0%
-99.41%
Ondine Biomedical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.47%
EBIT Growth (5y)
24.65%
EBIT to Interest (avg)
-20.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.42
Sales to Capital Employed (avg)
17.39
Tax Ratio
39.42%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
345.04%
ROE (avg)
123.78%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
16.79
EV to EBIT
18.99
EV to EBITDA
12.16
EV to Capital Employed
-36.69
EV to Sales
1.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
86.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1.20
0.70
71.43%
Operating Profit (PBDIT) excl Other Income
-10.80
-8.50
-27.06%
Interest
0.00
0.00
Exceptional Items
0.20
0.30
-33.33%
Consolidate Net Profit
-10.90
-8.60
-26.74%
Operating Profit Margin (Excl OI)
-9,489.50%
-12,306.70%
281.72%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 71.43% vs 75.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -26.74% vs 28.93% in Dec 2023
About Ondine Biomedical, Inc. 
Ondine Biomedical, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






